TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/18/24
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent ProgressGlobeNewsWire • 01/04/24
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 12/09/23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global OperationsGlobeNewsWire • 12/07/23
Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's WhyZacks Investment Research • 12/06/23
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and ExpositionGlobeNewsWire • 12/04/23
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology OfficerGlobeNewsWire • 12/04/23
Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect?Zacks Investment Research • 12/01/23
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive YearsGlobeNewsWire • 11/30/23
TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 11/27/23
TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 11/20/23
Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should KnowZacks Investment Research • 11/15/23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual MeetingGlobeNewsWire • 11/06/23
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 11/02/23
TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's WhyZacks Investment Research • 10/12/23
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 09/27/23
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAMEGlobeNewsWire • 08/29/23
TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 08/16/23
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/23